Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,531.86 +1,014.19 (+1.62%) CMC Crypto 200
1,336.15 -60.38 (-4.32%)
MedinCell S.A. (MDCLF)
- Business Wire
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
MONTPELLIER, France, April 16, 2024--Regulatory News: Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies. Medincell will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials. A
- Business Wire
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
MONTPELLIER, France, April 08, 2024--Regulatory News: Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM. If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission of malaria among vulnerable populations in high-transmission areas.
- Business Wire
MedinCell to Present at the 23rd Annual Needham Virtual Healthcare Conference
MONTPELLIER, France, March 27, 2024--Regulatory News: MedinCell (Paris:MEDCL) has recently reached the commercial stage with the market launch by Teva of UZEDY™ for the treatment of schizophrenia. UZEDY is the first innovative product based on MedinCell’s long-acting injectable (LAI) BEPO® technology approved by US FDA.
